Zentalis Pharmaceuticals (ZNTL) Non-Current Deferred Tax Liability (2019 - 2023)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Non-Current Deferred Tax Liability of $756000.0 for Q1 2023, down 51.16% year-over-year from $1.5 million in Q1 2022, and down 11.37% quarter-over-quarter from $853000.0 in Q4 2022.
Zentalis Pharmaceuticals (ZNTL) Non-Current Deferred Tax Liability (2019 - 2023) Analysis & Trends
Zentalis Pharmaceuticals' Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $756000.0 for Q1 2023.
- In Q1 2023, Non-Current Deferred Tax Liability fell 51.16% year-over-year to $756000.0; the TTM figure through Mar 2023 stood at $756000.0 (down 51.16% YoY), while the FY2022 annual figure was $853000.0, down 95.54% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2023 stood at $756000.0, down from $853000.0 in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $19.1 million in Q4 2021, with the low at $756000.0 in Q1 2023.
- The 5-year median for Non-Current Deferred Tax Liability is $2.5 million (2019), against an average of $3.1 million.
- The sharpest annual moves came in 2021 and 2022: Non-Current Deferred Tax Liability surged 671.77% in 2021, then tumbled 95.54% in 2022.
- Zentalis Pharmaceuticals' Non-Current Deferred Tax Liability stood at $2.5 million in 2019, then advanced by 0.69% to $2.5 million in 2020, then soared by 671.77% to $19.1 million in 2021, then sank by 95.54% to $853000.0 in 2022, then fell by 11.37% to $756000.0 in 2023.
- Business Quant data shows ZNTL's Non-Current Deferred Tax Liability at $756000.0 in Q1 2023, $853000.0 in Q4 2022, and $1.2 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 10.34 Mn |
| Dec 31, 2023 | 10.34 Mn |
| Mar 31, 2023 | 756,000.00 |
| Mar 31, 2023 | 756,000.00 |
| Dec 31, 2022 | 853,000.00 |
| Dec 31, 2022 | 853,000.00 |
| Sep 30, 2022 | 1.23 Mn |
| Sep 30, 2022 | 1.23 Mn |
| Jun 30, 2022 | 1.33 Mn |
| Jun 30, 2022 | 1.33 Mn |
| Mar 31, 2022 | 1.55 Mn |
| Mar 31, 2022 | 1.55 Mn |
| Dec 31, 2021 | 19.14 Mn |
| Dec 31, 2021 | 19.14 Mn |
| Sep 30, 2021 | 1.67 Mn |
| Sep 30, 2021 | 1.67 Mn |
| Jun 30, 2021 | 2.48 Mn |
| Jun 30, 2021 | 2.48 Mn |
| Mar 31, 2021 | 2.48 Mn |
| Mar 31, 2021 | 2.48 Mn |